PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:PHO - NO0010000045 - Common Stock
63 NOK
+1.2 (+1.94%)
PHO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. While PHO has a great health rating, there are worries on its profitability. PHO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHO was profitable.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of PHO (-0.78%) is worse than 60.00% of its industry peers.
The Return On Equity of PHO (-1.11%) is worse than 60.00% of its industry peers.
The Return On Invested Capital of PHO (0.11%) is worse than 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROIC | 0.11% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHO's Operating Margin of 0.17% is on the low side compared to the rest of the industry. PHO is outperformed by 65.45% of its industry peers.
PHO's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 93.40%, PHO belongs to the best of the industry, outperforming 94.55% of the companies in the same industry.
PHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
PHO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.12 indicates that PHO is not in any danger for bankruptcy at the moment.
PHO has a Altman-Z score of 6.12. This is amongst the best in the industry. PHO outperforms 85.45% of its industry peers.
PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.12 |
ROIC/WACC0.01
WACC8.5%
2.3 Liquidity
PHO has a Current Ratio of 4.78. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHO (4.78) is better than 98.18% of its industry peers.
PHO has a Quick Ratio of 4.29. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.29, PHO belongs to the top of the industry, outperforming 96.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.88%.
Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 4.94% in the last year.
Measured over the past years, PHO shows a quite strong growth in Revenue. The Revenue has been growing by 13.29% on average per year.
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
3.2 Future
PHO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 168.33% yearly.
Based on estimates for the next years, PHO will show a quite strong growth in Revenue. The Revenue will grow by 14.98% on average per year.
EPS Next Y485.3%
EPS Next 2Y167.97%
EPS Next 3Y168.33%
EPS Next 5YN/A
Revenue Next Year11.99%
Revenue Next 2Y9.24%
Revenue Next 3Y11.46%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 2100.00, PHO can be considered very expensive at the moment.
Based on the Price/Earnings ratio, PHO is valued a bit more expensive than the industry average as 67.27% of the companies are valued more cheaply.
PHO is valuated expensively when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 67.56, the valuation of PHO can be described as expensive.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than 67.27% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.59. PHO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2100 | ||
| Fwd PE | 67.56 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHO is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 61.82% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.17 | ||
| EV/EBITDA | 47.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHO does not grow enough to justify the current Price/Earnings ratio.
PHO's earnings are expected to grow with 168.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.33
PEG (5Y)N/A
EPS Next 2Y167.97%
EPS Next 3Y168.33%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (11/28/2025, 7:00:00 PM)
63
+1.2 (+1.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.64%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.71B
Revenue(TTM)525.39M
Net Income(TTM)-5.33M
Analysts82.5
Price Target81.6 (29.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.57%
Min EPS beat(2)15.13%
Max EPS beat(2)262.02%
EPS beat(4)3
Avg EPS beat(4)30.25%
Min EPS beat(4)-203.96%
Max EPS beat(4)262.02%
EPS beat(8)5
Avg EPS beat(8)48.5%
EPS beat(12)7
Avg EPS beat(12)20.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)3
Avg Revenue beat(8)-3.45%
Revenue beat(12)6
Avg Revenue beat(12)-2.68%
Revenue beat(16)7
Avg Revenue beat(16)-4.3%
PT rev (1m)0.63%
PT rev (3m)1.59%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.44%
EPS NY rev (3m)20.47%
Revenue NQ rev (1m)2.58%
Revenue NQ rev (3m)2.58%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)2.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2100 | ||
| Fwd PE | 67.56 | ||
| P/S | 3.27 | ||
| P/FCF | 49.17 | ||
| P/OCF | 37.09 | ||
| P/B | 3.56 | ||
| P/tB | 6.88 | ||
| EV/EBITDA | 47.61 |
EPS(TTM)0.03
EY0.05%
EPS(NY)0.93
Fwd EY1.48%
FCF(TTM)1.28
FCFY2.03%
OCF(TTM)1.7
OCFY2.7%
SpS19.28
BVpS17.69
TBVpS9.15
PEG (NY)4.33
PEG (5Y)N/A
Graham Number3.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROCE | 0.14% | ||
| ROIC | 0.11% | ||
| ROICexc | 0.18% | ||
| ROICexgc | 0.49% | ||
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% | ||
| FCFM | 6.65% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.76% | ||
| Cap/Sales | 2.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 | ||
| Altman-Z | 6.12 |
F-Score4
WACC8.5%
ROIC/WACC0.01
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
EPS Next Y485.3%
EPS Next 2Y167.97%
EPS Next 3Y168.33%
EPS Next 5YN/A
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
Revenue Next Year11.99%
Revenue Next 2Y9.24%
Revenue Next 3Y11.46%
Revenue Next 5Y14.98%
EBIT growth 1Y-97.81%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year125.85%
EBIT Next 3Y71.38%
EBIT Next 5YN/A
FCF growth 1Y-3.32%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y9.51%
OCF growth 3Y47.56%
OCF growth 5Y30.02%
PHOTOCURE ASA / PHO.OL FAQ
What is the fundamental rating for PHO stock?
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL.
Can you provide the valuation status for PHOTOCURE ASA?
ChartMill assigns a valuation rating of 1 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.
Can you provide the profitability details for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.
What is the valuation of PHOTOCURE ASA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PHOTOCURE ASA (PHO.OL) is 2100 and the Price/Book (PB) ratio is 3.56.
How financially healthy is PHOTOCURE ASA?
The financial health rating of PHOTOCURE ASA (PHO.OL) is 9 / 10.